Myriad Genetics Inc (MYGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $542.92M
Last updated: Nov 17, 2026 at 4:15 PM ET
Myriad Genetics Inc (MYGN) Stock Chart
Myriad Genetics (MYGN) has a latest price of $5.54 on Nov 17, 2026, 31.5% below its 52-week high of $8.09. Its price fell 17.4% over the past 12 months. The month-end price fell 67.8% over the 10 years through Oct 2026, a compound annual decline of 10.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $49.79 in Aug 2018 and its lowest $2.86 in Jul 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart MYGN with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for MYGN.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 73.7%, and over 6 months it rose 56.1%. The month-end price fell 59.2% over the 3 years through Oct 2026, a compound annual decline of 25.9%.
| Period | Change |
|---|---|
| 1 month | +31.6% |
| 3 months | +73.7% |
| 6 months | +56.1% |
| 12 months | -17.4% |
| 12 months, with dividends | -17.4% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -59.2% | -25.9% |
| 5 years | -79.4% | -27.1% |
| 10 years | -67.8% | -10.7% |
Price by Year
Its best calendar year was 2017, when the price rose 106.1%, and its weakest was 2025, when it fell 55.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $6.35 | +3.3% |
| 2025 | $6.15 | -55.1% |
| 2024 | $13.71 | -28.4% |
| 2023 | $19.14 | +31.9% |
| 2022 | $14.51 | -47.4% |
| 2021 | $27.60 | +39.6% |
| 2020 | $19.77 | -27.4% |
| 2019 | $27.23 | -6.3% |
| 2018 | $29.07 | -15.4% |
| 2017 | $34.35 | +106.1% |
Trading Range
The price is 14.4% above its 50-day average of $4.84 and 20.2% above its 200-day average of $4.61.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $5.54 | |
| 52-week high | $8.09 | -31.5% |
| 52-week low | $2.74 | +102.2% |
| 50-day average | $4.84 | +14.4% |
| 200-day average | $4.61 | +20.2% |
Price Risk
Over 3 years, its largest fall from a peak was 90.0%.
| Measure | Value |
|---|---|
| 1-year beta | 0.63 |
| Largest fall, 1 year | -63.8% |
| Largest fall, 3 years | -90.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About MYGN
What is MYGN's 1-year price change?
Myriad Genetics's price fell 17.4% over the past 12 months. With dividends included, the 12-month total return was -17.4%.
What is MYGN's 5-year price change?
Myriad Genetics's month-end price fell 79.4% over the 5 years through Oct 2026, a compound annual decline of 27.1%. These figures leave out dividends.
What is MYGN's 52-week high and low?
Myriad Genetics's 52-week high is $8.09 and its 52-week low is $2.74. Its latest price of $5.54 on Nov 17, 2026 is 31.5% below the high.
What is MYGN's beta?
Myriad Genetics's 1-year beta against the S&P 500 is 0.63, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 63.8%.
Is the MYGN chart free?
Yes. Advanced Charting for MYGN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
MYGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts